Otobrol (Ondansetron)

Ondansetron, the active ingredient in Otobrol, is a 5-HT3 receptor antagonist presented as a tablet for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Otobrol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Otobrol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is used to manage nausea and vomiting by targeting the serotonergic pathways involved in emesis.

- Chemotherapy‑induced nausea and vomiting: helps prevent and control acute and delayed episodes. - Radiation‑induced nausea and vomiting: reduces the frequency and severity of symptoms. - Post‑operative nausea and vomiting: decreases the incidence of nausea after surgical procedures.

Side effects reported with ondansetron are generally mild to moderate and vary by individual.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement difficulty. - Diarrhoea: loose stools in some patients. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation may lead to irregular heart rhythms. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Serotonin syndrome: rare but potentially life‑threatening condition when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes indicating liver stress. - Vision changes: blurred or altered visual perception.

When using Ondansetron, consider the following safety measures:

- Cardiac monitoring: patients with known QT prolongation or electrolyte imbalance should be observed. - Drug interactions: review concomitant medications for serotonergic activity. - Pregnancy: use only if the potential benefit outweighs risk; consult obstetric guidance. - Breastfeeding: weigh benefits against potential infant exposure. - Renal or hepatic impairment: dose adjustment may be required based on clinical judgment. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Apomorphine: may cause profound hypotension and loss of consciousness. - Certain anti‑arrhythmic drugs (e.g., amiodarone, quinidine): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely): - Serotonergic agents (SSRIs, SNRIs, MAO inhibitors): may raise serotonin syndrome risk. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can elevate ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampicin): may reduce ondolanetil